Uncertain translation, uncertain benefit and uncertain risk: Ethical challenges facing first-in-human trials of induced pluripotent stem (ips) cells

Bioethics

Volumn 27, Issue 2, 2013, Pages 89-96

  Fung, Ronald K F ^a   Kerridge, Ian H ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

First in human trials; Parkinson's disease; Research ethics; Risk; Stem cells

Indexed keywords

ARTICLE; ETHICS; HUMAN; HUMAN EXPERIMENT; INFORMED CONSENT; PARKINSON DISEASE; PATIENT SELECTION; PLURIPOTENT STEM CELL; RISK ASSESSMENT; RISK MANAGEMENT; STEM CELL TRANSPLANTATION; TRANSLATIONAL RESEARCH; TRANSPLANTATION; UNCERTAINTY;

HUMAN EXPERIMENTATION; HUMANS; INDUCED PLURIPOTENT STEM CELLS; INFORMED CONSENT; PARKINSON DISEASE; PATIENT SELECTION; RISK ASSESSMENT; RISK MANAGEMENT; STEM CELL TRANSPLANTATION; TRANSLATIONAL MEDICAL RESEARCH; UNCERTAINTY;

EID: 84872489192     PISSN: 02699702     EISSN: 14678519     Source Type: Journal    
DOI: 10.1111/j.1467-8519.2011.01896.x     Document Type: Article

References (45)

1. National Institutes of Health, US Department of Health and Human Services. 2009. The National Institutes of Health resource for stem cell research: Stem Cell Basics. Bethesda, MD. Available at: http://stemcells.nih.gov/info/basics/defaultpage2010
2. Y. Hotta. Ethical Issues of the Research on Human Embryonic Stem Cells. J Int Bioethique 2008; 19: 77-85.
3. K.H. Campbell et al. Sheep Cloned by Nuclear Transfer from a Cultured Cell Line. Nature 1996; 380: 64-66.
4. G. Pennings et al. ESHRE Task Force on Ethics and Law 12: Oocyte Donation for Non-reproductive Purposes. Hum Reprod 2007; 22: 1210-1213.
5. K. Takahashi et al. Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors. Cell 2007; 131: 861-872.
6. J. Yu & J.A. Thomson. Pluripotent Stem Cell Lines. Genes Dev 2008: 22: 1987-1997.
7. M.H. Chin et al. Induced Pluripotent Stem Cells and Embryonic Stem Cells are Distinguished by Gene Expression Signatures. Cell Stem Cell 2009; 5: 111-123.
8. Q. Feng et al. Hemangioblast Derivatives from Human Induced Pluripotent Stem Cells Exhibit Limited Expansion and Early Senescence. Stem Cells 2010; 28: 704-712.
9. E. Kiskinis & K. Eggan. Progress Toward the Clinical Application of Patient-specific Pluripotent Stem Cells. J Clin Invest 2010; 120: 51-59.
10. M.L. Condic, P. Lee & R.P. George. Ontological and Ethical Implications of Direct Nuclear Reprogramming: Response to Magill and Neaves. Kennedy Inst Ethics J 2009; 19: 33-40.
11. F. Baylis. 2008. ES Cells and iPS Cells: A Distinction with a Difference. Garrison, NY: The Hastings Center. Available athttp://www.thehastingscenter.org/Bioethicsforum/Post.aspx?id=7302010
12. A. Zarzeczny et al. IPS Cells: Mapping the Policy Issues. Cell 2009; 139: 1032-1037.
13. N. Caballol, M.J. Martí & E. Tolosa. Cognitive Dysfunction and Dementia in Parkinson Disease. Mov Disord 2007; 22: S358-S366.
14. A. Samii, J.G. Nutt & B.R. Ransom. Parkinson's Disease. Lancet 2004; 363: 1783-1793.
15. B.P. Bejjani et al. Transient Acute Depression Induced by High-frequency Deep-brain Stimulation. N Engl J Med 1999; 340: 1476-1480.
16. M. Wernig et al. Neurons Derived from Reprogrammed Fibroblasts Functionally Integrate into the Fetal Brain and Improve Symptoms of Rats with Parkinson's Disease. Proc Natl Acad Sci U S A. 2008; 105: 5856-5861.
17. S. Muramatsu et al. Multitracer Assessment of Dopamine Function after Transplantation of Embryonic Stem Cell-derived Neural Stem Cells in a Primate Model of Parkinson's Disease. Synapse 2009; 63: 541-548.
18. World Medical Association (WMA). 2008. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. Ferney-Voltaire, France: WMA. Available at: http://www.wma.net/en/30publications/10policies/b3/index.html2010.
19. International Society for Stem Cell Research (ISSCR). 2008. Guidelines for the Clinical Translation of Stem Cells. Deerfield, IL: ISSCR. Available at: http://www.isscr.org/clinical_trans/pdfs/ISSCRGLClinicalTrans.pdf2010
20. R. Dresser. First-in-Human Trial Participants: Not a Vulnerable Population, but Vulnerable Nonetheless. J Law Med Ethics 2009; 37: 38-50.
21. C.R. Freed et al. Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease. N Engl J Med 2001; 344: 710-719.
22. K. Okita, T. Ichisaka & S. Yamanaka. Generation of Germline-Competent Induced Pluripotent Stem Cells. Nature 2007; 448: 313-317.
23. L. Dawson et al. Safety Issues in Cell-based Intervention Trials. Fertil Steril 2003; 80: 1077-1085.
24. M.U. Fareed & F.L. Moolten. Suicide Gene Transduction Sensitizes Murine Embryonic and Human Mesenchymal Stem Cells to Ablation on Demand - a Fail-safe Protection against Cellular Misbehavior. Gene Ther 2002; 9: 955-962.
25. M. Chen et al. Role of MEF Feeder Cells in Direct Reprogramming of Mousetail-tip Fibroblasts. Cell Biol Int 2009; 33: 1268-1273.
26. K. Takahashi et al. Human Induced Pluripotent Stem Cells on Autologous Feeders. PLoS One 2009; 4: e8067.
27. E. Lane & S. Dunnett. Animal Models of Parkinson's Disease and L-dopa Induced Dyskinesia: How Close Are We to the Clinic? Psychopharmacology (Berl) 2008; 199: 303-312.
28. E.J. Frackiewicz et al. Brasofensine Treatment for Parkinson's Disease in Combination with Levodopa/carbidopa. Ann Pharmacother 2002; 36: 225-230.
29. J. Kimmelman. 2010. Gene transfer and the ethics of first-in-human research: lost in translation. Cambridge, UK: Cambridge University Press.
30. L.D. Shultz, F. Ishikawa & D.L. Greiner. Humanized Mice in Translational Biomedical Research. Nat Rev Immunol 2007; 7: 118-130.
31. H. LaFollette & N. Shanks. The Origin of Speciesism. Philosophy 1996; 71: 41-61
32. J. Rachels. 1990. Created from Animals. Oxford: Oxford University Press: 220. According to the theory of 'causal functional asymmetry', the logical dilemma arises where the assertion that humans and non-human animals share significant biological mechanisms, such that experiments on the latter can shed light on the former, seems to be at odds with the claim that they are, at the same time, substantially different as far as moral capacity is concerned. As Rachels succinctly puts it, 'If the animal subjects are not sufficiently like us to produce a model, then the experiments may be pointless. but if the animals are enough like us to provide a model, it may be impossible to justify treating them in ways we would not treat humans
33. Editorial. Reduce, refine, replace. Nature Immunol 2010; 11: 971.
34. S.K. Inouye & L. Ferrucci. Elucidating the Pathophysiology of Delirium and the Interrelationship of Delirium and Dementia. J Gerontol A Biol Sci Med Sci 2006; 61: 1277-1280.
35. M.F. Folstein, S.E. Folstein & P.R. McHugh. Mini-mental state. A Practical Method for Grading the Cognitive State of Patients for the Clinician. J Psychiatr Res 1975; 12: 189-198.
36. B. Cullen et al. A Review of Screening Tests for Cognitive Impairment. J Neurol Neurosurg Psychiatry 2007; 78: 790-799.
37. P.S. Appelbaum et al. Competence of Depressed Patients for Consent to Research. Am J Psychiatry 1999; 156: 1380-1384.
38. S.Y. Kim & E.D. Caine. Utility and Limits of the Mini Mental State Examination in Evaluating Consent Capacity in Alzheimer's disease. Psychiatr Serv 2002; 53: 1322-1324.
39. B.S. Black et al. Predictors of Providing Informed Consent or Assent for Research Participation in Assisted Living Residents. Am J Geriatr Psychiatry 2008; 16: 83-91
40. D.J. Mathews et al. Cell-based Interventions for Neurologic Conditions: Ethical Challenges for Early Human Trials. Neurology 2008; 71: 288-293.
41. L.C. Kaldjian et al. Dementia, Goals of Care, and Personhood: a Study of Surrogate Decision Makers' Beliefs and Values. Am J Hosp Palliat Care 2010; 27: 387-397.
42. Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, Social Sciences and Humanities Research Council of Canada. 1998. Tri-council policy statement: Ethical conduct for research involving humans. Ottawa, ON. Available at:http://pre.ethics.gc.ca/eng/policy-politique/tcps-eptc2010
43. R. Pierce. A Changing Landscape for Advance Directives in Dementia Research. Soc Sci Med 2010; 70: 623-630.
44. For a more detailed analysis of the phenomenon of therapeutic misconception which is widely observed in clinical research, see: N.M. King et al. Consent Forms and the Therapeutic Misconception: the Example of Gene Transfer Research. 2005; 27: 1-8
45. T. Caulfield et al. Stem Cell Research Policy and iPS Cells. Nat Methods 2010; 7: 28-33.